Kiniksa Pharmaceuticals Q2 Adj EPS $(0.02) Beats $(0.17) Estimate, Sales $71.47M Beat $52.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kiniksa Pharmaceuticals reported Q2 earnings of $0.21 per share, beating the analyst consensus estimate of $(0.17) by 223.53%. The company also reported quarterly sales of $71.47 million, surpassing the analyst consensus estimate of $52.20 million by 36.92%. This represents a 172.41% increase in earnings and a 164.99% increase in sales compared to the same period last year.
July 25, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kiniksa Pharmaceuticals reported significantly higher Q2 earnings and sales than expected, indicating strong performance.
Kiniksa Pharmaceuticals reported Q2 earnings and sales that significantly exceeded analyst estimates. This indicates strong performance and could lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100